Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics to improve patient care.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/07/15 | $195,000,000 | Series F |
Alexandria Real Estate Equities Casdin Capital Matrix Capital Management Rock Springs Capital Senator Investment Group Tiger Global Management Viking Global Investors | undisclosed |
